Technologies Found (148)
Array ( [cache_time] => 0 [counts_time] => 0 [query_time] => [category_counts_time] => 0 [total_time] => 0 )
Technology NameBriefcaseLead Researcher
  Background Many kinds of surfaces are notorious sources of infection. Eradication of bacteria immobilized as biofilms on these surfaces is a major biological problem. Prevention of the development of biofilms is of prime concern to ...
More
Friedman Michael
Once-daily, sustained-release Sirolimus delivery system Categories Oral Cavity, Oncology/Cancer, Sustained Release, Drug Delivery Development Stage Prototypes tested in vitro; pharmokinetic and pharmacodynamic testing in human volunteers ...
More
Friedman Michael
Background Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders. CB1 agonists (such as the ...
More
Mechoulam Raphael
Background Metal based anti-tumor therapeutics Cisplatin and Carboplatin are two of the most widely prescribed anticancer agents. However, not all tumors can be treated with Cisplatin. In addition, Cisplatin may cause an extremely toxic ...
More
Tshuva Edit
  Background With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs, including peptides. Our Innovation Platform ...
More
Touitou Elka
 Background Quorum sensing takes place in biofilms where microbes such as bacteria and fungi are at close proximity to one another Inter species quorum sensing may affect microbes’ physiology and virulence properties, resulting in the ...
More
Steinberg Doron
Highlights Prevention of IgE-mediated allergic reaction by blocking and clearing pollen allergens with oxidized cellulose via its polysaccharide binding domain. Mode of administration: inhalation, intranasal, ocular, topical and ...
More
Shoseyov Oded
  Background DNA mutations in mitochondrial proteins/enzymes (nuclear encoded) that may lead to disease are present in approximately 1 in 8,000 individuals. Any treatment for mitochondrial diseases must be capable of targeting and crossing the ...
More
Galski- Lorberboum Haya